Navigation Links
Pilot Study Opens the Door for Avastin Use in Curative Setting for Women With Breast Cancer
Date:12/17/2007

Roche in collaboration with Genentech commit to large phase III adjuvant

clinical programme set to unlock Avastin's potential in early breast

SAN ANTONIO, Dec. 17 /PRNewswire/ -- According to new phase II study data, Avastin (bevacizumab) can proceed to be tested after breast cancer surgery in combination with anthracycline containing regimens. These findings pave the way for Avastin's use as a curative treatment for women with this devastating disease. Data presented today at the San Antonio Breast Cancer Symposium (SABCS) from the E2104 study showed that standard anthracycline-based chemotherapy (doxorubicin) can be added to Avastin after surgical removal of the breast tumour, without a concerning increase in the incidence of cardiac adverse events typically associated with this form of chemotherapy.

These data support the commencement of phase III adjuvant breast cancer clinical programme which will include over 10,000 patients with early stage breast cancer. Avastin already offers women with late-stage (metastatic) breast cancer the chance to live twice as long without their disease progressing (1).

"The unique way Avastin works also lends itself for use in women with earlier stages of breast cancer" said Dr Kathy Miller of Indiana University School of Medicine, USA and principal investigator of the E2104 study. "We now know that Avastin use in combination with anthracyclines does not result in concerning rates of cardiac dysfunction in the adjuvant setting and armed with this evidence Avastin's impact can be fully validated in a large worldwide phase III clinical trial programme."

Data from the E2104 study have shown that cardiac dysfunction is not a major concern with the treatment combination of Avastin and doxorubicin. As presented in SABCS, two patients with symptomatic congestive heart failure were reported in each of the 2 Avastin-containing treatment arms which included more than 100 patie
'/>"/>

SOURCE Roche
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) and Boston Scientifics Taxus(R) Stent in Patients at High Risk of Restenosis
2. PLC Systems Achieves Successful Early Conclusion of RenalGuard(TM) Pilot Safety Trial
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
7. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
10. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
11. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/15/2008)...cellent results obtained with a newly cleared devi...laques of interest that are associated with ...URLINGTON, Mass., May 15 /- InfraReDx... Hospital in Royal Oak, Mich., have,successfully u...patient,undergoing a cardiac catheterization. This...
(Date:5/15/2008)...OSTON, May 15 /- CenterWatch, a publi...market research about clinical,trials, finds that ... EDC,(electronic data capture) systems. More than ...indicated that they had been trained on three or m... that the effectiveness of,their EDC training had ...
(Date:5/15/2008)...derable Opportunity Remains for an Antiplatelet Th...eeding than the Combination of Plavix/Iscover ...on Resources, WALTHAM, Mass., May 15 /PRNewswire/... research and advisory firms for pharmaceutical an... Lilly,s Effient offers,improvement in patient com...
(Date:5/15/2008)...andomized TRIAS HR Pilot Study Compares Genous, Bo...axus(R), Other Presentations Focus on Real-World U...h AMI, Those Who Could Not Tolerate Dual-Antiplate...LONA, Spain, May 15 /- OrbusNeich tod...ions in a symposium at EuroPCR 2008,support the us...
Breaking Medicine Technology:First Use in a Patient of The InfraReDx LipiScan(TM) Coronary Imaging System 2First Use in a Patient of The InfraReDx LipiScan(TM) Coronary Imaging System 3First Use in a Patient of The InfraReDx LipiScan(TM) Coronary Imaging System 4CenterWatch Releases State of the Clinical Trials Industry 2008 - A Key Industry Resource for Market Research and Competitive Intelligence 2Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction 2Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction 3Multiple Clinical Data Presentations at EuroPCR 2008 Support Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) as Safe Alternative to Drug-Eluting Stents 2Multiple Clinical Data Presentations at EuroPCR 2008 Support Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) as Safe Alternative to Drug-Eluting Stents 3Multiple Clinical Data Presentations at EuroPCR 2008 Support Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) as Safe Alternative to Drug-Eluting Stents 4Experimental Drug Fails Against Heart Failure 5670 1Experimental Drug Fails Against Heart Failure 5670 2Experimental Drug Fails Against Heart Failure 5670 3Unlocking the function of enzymes 1130 1Unlocking the function of enzymes 1130 2AcroMetrix Announces Launch of PeliSpy Chagas Positive Control 5665 1Health Care Tops Issues Voters in Early Primary States Want 2008 Presidential Candidates to Address 5662 1Health Care Tops Issues Voters in Early Primary States Want 2008 Presidential Candidates to Address 5662 2
... BOSTON, April 25, 2007 /PRNewswire-USNewswire/ -...bipolar disorder first,appear in childhood or adol... to distinguish bipolar symptoms from those of oth...ard Mental Health,Letter. , Children, especially y... of distinct mood episodes of mania and depression...
... LANGENFELD, Germany, April 25, 2007-Labtec GmbH ...ompany announces positive,results from a multiple ...il transdermal patch. , “Today, we are pleas...cond clinical trial for our Sufentanil,TDS®. O...y in,the first half of 2007,” says Dr. Armin...
Other Medicine Technology:Bipolar Disorder in Children Difficult to Diagnose, Reports the,Harvard Mental Health Letter 2Labtec’s Next Generation Pain Patch Successful in Clinical,Studies 2
(Date:5/16/2008)...ocs determine who would benefit most from chemo af...16 (HealthDay News) -- A panel of 15 genes may hel...all cell lung cancer will experience a recurrence ..., a new study shows. , By extension, the same ...less aggressive forms of the cancer who would be a...
(Date:5/16/2008)...ON, May 16 /PRNewswire-USNewswire/ -- As tropical ... Irrawaddy delta, survivors of,Cyclone Nargis are ...Many,survivors still need assistance, as exposure ...an increasingly dire situation., "The people livi...recover from this disaster and get back on their f...
(Date:5/16/2008)... Funding Per Death Drops More in 2007, WASHINGTON...cer causes,one in three cancer deaths, the Nationa...its $4.8 billion budget in lung cancer research in...ung Cancer Alliance (LCA) today., The two other f...rograms -- Centers for Disease Control and Prevent...
(Date:5/16/2008)...O, May 16 /PRNewswire-FirstCall/ -- CryoCor, Inc. ...n the treatment of cardiac,arrhythmias, announced ...CryoCor common stock filed a complaint in the Supe...an Diego, naming as defendants each member of the,...Scientific Corporation.,The complaint is styled Se...
Breaking Medicine News(10 mins):Health News:Gene Signature May Predict Recurrence of Lung Cancer 2Health News:Gene Signature May Predict Recurrence of Lung Cancer 3Health News:Myanmar Cyclone Survivors Face New Challenges 2Health News:Lung Cancer Still Lowest in Federal Funding 2Health News:CryoCor, Inc. Subject of Lawsuit Relating to Tender Offer and Merger 2Health News:CryoCor, Inc. Subject of Lawsuit Relating to Tender Offer and Merger 3Health News:CryoCor, Inc. Subject of Lawsuit Relating to Tender Offer and Merger 4
...tial to protect the kidneys from failing after inj...mice were genetically engineered to express higher...c growth factor (HGF) or another natural factor ca...in (PTHrP). Both groups of mice developed normal k...
...cted SARS case in six months may have the coronavi...was waiting for more results to come in.// "There...cted the SARS coronavirus," Xu Ruiheng, deputy dir...ses prevention and control, said on Hong Kong cabl...
...y combat death, heart attack and repeat procedures...ffects of drug-coated stents on patients.// The s...ly untreated blocked arteries who were treated wit...450 patients with comparable blockages were treate...
...nce it interferes with eating and drinking. Childr...y do not realize the importance of maintaining// t...y reveals that a tonsillectomy procedure using les...y be the key to reducing pain during recovery.<...
Other Medicine News:Health News:New Hope for Kidney Failure 2
Drug controls sera available in three levels for the control of accuracy and percision for up to 18 analytes
Sera available in three levels for the control of accuracy and precision for up to 31 analytes
Human based material available in two levels for thecontrol of percision for up to 10 analytes
Human based material available in two levels for the control of accuracy and precision for upto 23 analytes.
Medicine Products: